or
forgot password

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Carcinoma

Thank you

Trial Information

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma


- MRI's will be performed at specific time points during the participants treatment for
renal cell carcinoma with the drug sunitinib or pazopanib. These ASL MRI's will be
performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib,
after cycle 2 and/or cycle 4 of therapy, and at the end of therapy.

- The MRI tests for all participants will be done at Beth Israel Deaconess Medical
Center.


Inclusion Criteria:



- Patients diagnosed with metastatic renal cell carcinoma and who will initiate
sunitinib or pazopanib

- Enrolled on protocol 06-105, "Collection of specimens and clinical data from patients
with renal cell carcinoma treated with targeted therapies," or receiving Pazopanib as
part of routine clinical care.

- Found to have tumors that are 2.5cm or greater as determined by CT imaging

- Candidate lesions for ASL MRI should be 2.5cm or greater. Order of preference of
lesion location will be as follows: abdominal lesions, bone lesions and chest lesions

Exclusion Criteria:

- Contraindication to MRI

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To explore the association of baseline blood flow in renal cell carcinoma measured by ASL MRI and tumor response to treatment with sunitinib or pazopanib

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Maryellen Sun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beth Israel Deaconess Medical Center

Authority:

United States: Institutional Review Board

Study ID:

08-078

NCT ID:

NCT00749320

Start Date:

September 2008

Completion Date:

November 2013

Related Keywords:

  • Renal Cell Carcinoma
  • MRI
  • Sunitinib
  • Pazopanib
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115